Tirzepatide 10mg

Description

• Superior Weight Management: In Phase III clinical trials (SURMOUNT), research subjects demonstrated an average body weight reduction of 15% to 22%, depending on the dosage and protocol.

• Glycemic Control: Heavily researched for its ability to lower HbA1c levels by up to 2.5%, significantly improving insulin sensitivity and pancreatic beta-cell function.

• Visceral & Liver Fat Reduction: Studied for its role in promoting fat oxidation and reducing hepatic (liver) fat by up to 37%, offering potential insights into MASH/NAFLD research.

• Cardiometabolic Optimization: Research indicates positive impacts on systemic inflammatory markers, blood pressure, and lipid profiles (cholesterol and triglycerides).

• Appetite & Satiety Signaling: Investigated for its ability to slow gastric emptying and modulate dopamine-related food reward systems in the brain.

Research Use Only: This product is intended for laboratory research purposes only. It is not approved by the FDA for human consumption or for the treatment of obesity or diabetes.